About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 128 record(s)
Req # A-2020-000875
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-108169-259, Exposure Notification - Consultation with the Office of the Privacy Commissioner.Organization: Health Canada
July 2021
Req # A-2020-001923
Adverse Reaction Reports (AERs) for Abilify. Report numbers: E2B_03357016, E2B_03433811, E2B_03438670, E2B_03445919, E2B_03448513, E2B_03451979, E2B_03452092, E2B_03452152, E2B_03452156, E2B_03452168, E2B_03452227, E2B_03452236, E2B_03452237, E2B_03452256, E2B_03452263.Organization: Health Canada
July 2021
Req # A-2021-000036
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-103397-8, Classification Action within the COVID-19 Vaccine Roll-out Task-Force.Organization: Health Canada
July 2021
Req # A-2021-000064
Adverse Drug Reaction (ADR) for BISACODYL. Report number: E2B_02559487.Organization: Health Canada
July 2021
Req # A-2021-000090
Adverse Drug Reaction (ADR) for BISACODYL. Report number: E2B_03578861.Organization: Health Canada
July 2021
Req # A-2021-000149
Adverse Drug Reaction (ADR). Report number: E2B_03590702.Organization: Health Canada
July 2021
Req # A-2021-000172
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03742598.Organization: Health Canada
July 2021
Req # A-2021-000175
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03759475.Organization: Health Canada
July 2021
Req # A-2021-000176
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03745244.Organization: Health Canada
July 2021
Req # A-2021-000178
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03744369.Organization: Health Canada
July 2021